Results 21 to 30 of about 4,584 (134)

Dual Fc optimization to increase the cytotoxic activity of a CD19-targeting antibody

Frontiers in Immunology, 2022
Targeting CD19 represents a promising strategy for the therapy of B-cell malignancies. Although non-engineered CD19 antibodies are poorly effective in mediating complement-dependent cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC)
Carina Lynn Gehlert, Pegah Rahmati, Ammelie Svea Boje, Dorothee Winterberg, Steffen Krohn, Thomas Theocharis, Elisa Cappuzzello, Anja Lux, Falk Nimmerjahn, Ralf J. Ludwig, Marta Lustig, Thies Rösner, Thomas Valerius, Denis Martin Schewe, Christian Kellner, Katja Klausz, Matthias Peipp   +16 more
doaj   +1 more source

MOGAD patient autoantibodies induce complement, phagocytosis, and cellular cytotoxicity

JCI Insight, 2023
Myelin oligodendrocyte glycoprotein (MOG) antibody–associated disease (MOGAD) is an inflammatory demyelinating CNS condition characterized by the presence of MOG autoantibodies.
Soumya S. Yandamuri, Beata Filipek, Abeer H. Obaid, Nikhil Lele, Joshua M. Thurman, Naila Makhani, Richard J. Nowak, Yong Guo, Claudia F. Lucchinetti, Eoin P. Flanagan, Erin E. Longbrake, Kevin C. O’Connor   +11 more
doaj   +1 more source

Phagocytosis by an HIV antibody is associated with reduced viremia irrespective of enhanced complement lysis

Nature Communications, 2022
While antibodies neutralize HIV via Fab recognition of viral surface antigens, antibody Fc domains mediate effector functions, including antibody-dependent cellular phagocytosis (ADCP) and cytotoxicity (ADCC), and complement (C') activity.
David A. Spencer, Benjamin S. Goldberg, Shilpi Pandey, Tracy Ordonez, Jérémy Dufloo, Philip Barnette, William F. Sutton, Heidi Henderson, Rebecca Agnor, Lina Gao, Timothée Bruel, Olivier Schwartz, Nancy L. Haigwood, Margaret E. Ackerman, Ann J. Hessell   +14 more
doaj   +1 more source

Mechanisms of Action of the New Antibodies in Use in Multiple Myeloma

Frontiers in Oncology, 2021
Monoclonal antibodies (mAbs) directed against antigen-specific of multiple myeloma (MM) cells have Fc-dependent immune effector mechanisms, such as complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), and antibody ...
Alessandra Romano, Paola Storti, Valentina Marchica, Grazia Scandura, Laura Notarfranchi, Luisa Craviotto, Luisa Craviotto, Francesco Di Raimondo, Francesco Di Raimondo, Nicola Giuliani   +9 more
doaj   +1 more source

Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma

Cells, 2020
Daratumumab (Dara) is the first-in-class human-specific anti-CD38 mAb approved for the treatment of multiple myeloma (MM). Although recent data have demonstrated very promising results in clinical practice and trials, some patients do not achieve a ...
Ilaria Saltarella, Vanessa Desantis, Assunta Melaccio, Antonio Giovanni Solimando, Aurelia Lamanuzzi, Roberto Ria, Clelia Tiziana Storlazzi, Maria Addolorata Mariggiò, Angelo Vacca, Maria Antonia Frassanito   +9 more
doaj   +1 more source

Expansion Microscopy Reveals the Spatial Association of Therapeutic Antibody–Receptor Complexes With Cholesterol‐Rich Membrane Domains

Angewandte Chemie, Volume 138, Issue 42, 12 October 2026.
We report a super‐resolution strategy that maps cholesterol‐rich membrane domains in whole, intact cells with an effective spatial resolution of ∼40 nm by combining expansion microscopy with a perfringolysin O domain 4 probe. This approach enables direct visualization of the spatial association between CD20 and CD38 complexes and cholesterol‐rich ...
Gang Wen, Nicole Seifert, Patrick Eiring, Johanna Meyer, Hannes Neuweiler, Julia Weingart, Ignacio Vega‐Vásquez, Sören Doose, Philip Kollmannsberger, Markus Sauer   +9 more
wiley   +2 more sources

Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma

Journal of Hematology & Oncology, 2016
Daratumumab is a human monoclonal antibody that targets CD38, a cell surface protein that is overexpressed on multiple myeloma (MM) cells. Preclinical studies have shown that daratumumab induces MM cell death through several mechanisms, including ...
Larysa Sanchez, Yucai Wang, David S. Siegel, Michael L. Wang   +3 more
doaj   +1 more source

CD24 Is a Potential Immunotherapeutic Target for Mantle Cell Lymphoma

Biomedicines, 2022
CD24 and its ligand Siglec-10 were described as an innate immune checkpoint in carcinoma. Here, we investigated this axis in B-cell lymphoma by assessing CD24 expression and evaluating pro-phagocytic effects of CD24 antibody treatment in comparison to ...
Jimena Álvarez Freile, Natasha Ustyanovska Avtenyuk, Macarena González Corrales, Harm Jan Lourens, Gerwin Huls, Tom van Meerten, Ewa Cendrowicz, Edwin Bremer   +7 more
doaj   +1 more source

Antibody-Dependent Cellular Phagocytosis in Antiviral Immune Responses

Frontiers in Immunology, 2019
Antiviral activities of antibodies may either be dependent only on interactions between the antibody and cognate antigen, as in binding and neutralization of an infectious virion, or instead may require interactions between antibody–antigen immune ...
Matthew Zirui Tay, Kevin Wiehe, Justin Pollara, Justin Pollara   +3 more
doaj   +1 more source

LALAPG variant of the Human Contraception Antibody (HCA) reduces Fc-mediated effector functions while maintaining sperm agglutination activity.

PLoS ONE, 2023
High rates of unintended pregnancies worldwide indicate a need for more accessible and acceptable methods of contraception. We have developed a monoclonal antibody, the Human Contraception Antibody (HCA), for use by women in vaginal films and rings for ...
Emilie Mausser, Ellena Nador, Joseph A Politch, Michael R Pauly, Jai G Marathe, Thomas R Moench, Larry Zeitlin, Kevin J Whaley, Deborah J Anderson   +8 more
doaj   +2 more sources